These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8904625)

  • 1. Alpha-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility.
    Marshall HJ; Beevers DG
    Br J Clin Pharmacol; 1996 Oct; 42(4):507-9. PubMed ID: 8904625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    Kyprianou N
    J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha 1-adrenergic blockers: do they have a place in the prophylaxis of migraine?
    Vatz KA
    Headache; 1997 Feb; 37(2):107-8. PubMed ID: 9074296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
    Reid JL; Vincent J
    Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
    Samli MM; Dincel C
    Urol Int; 2004; 73(2):125-9. PubMed ID: 15331896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
    Louis WJ; McNeil JJ; Anavekar SN; Conway EL; Workman B; Howes LG; Drummer OH; Jarrott B
    J Cardiovasc Pharmacol; 1987; 10 Suppl 12():S100-3. PubMed ID: 2455158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.
    Kyprianou N; Jacobs SC
    Curr Urol Rep; 2000 Aug; 1(2):89-96. PubMed ID: 12084321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
    Thomas D; Wimmer AB; Wu K; Hammerling BC; Ficker EK; Kuryshev YA; Kiehn J; Katus HA; Schoels W; Karle CA
    Naunyn Schmiedebergs Arch Pharmacol; 2004 May; 369(5):462-72. PubMed ID: 15098086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terazosin: a new alpha adrenoceptor blocking drug.
    Achari R; Laddu A
    J Clin Pharmacol; 1992 Jun; 32(6):520-3. PubMed ID: 1353083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of alpha1-adrenergic blockers in boys with low urinary flow rate and urinary incontinence.
    Yang SS; Wang CC; Chen YT
    J Formos Med Assoc; 2003 Aug; 102(8):551-5. PubMed ID: 14569320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
    Belayneh M; Korownyk C
    Can Fam Physician; 2016 Sep; 62(9):e523. PubMed ID: 27629686
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
    Hamilton CA; Reid JL; Vincent J
    Br J Pharmacol; 1985 Sep; 86(1):79-87. PubMed ID: 2864970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Stockamp K
    Urologe A; 1995 Jan; 34(1):3-8. PubMed ID: 7533449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
    Jansen DJ; Resch ND; Hoffman RM
    Am J Health Syst Pharm; 1999 Jul; 56(13):1351. PubMed ID: 10683137
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
    Harris AM; Warner BW; Wilson JM; Becker A; Rowland RG; Conner W; Lane M; Kimbler K; Durbin EB; Baron AT; Kyprianou N
    J Urol; 2007 Nov; 178(5):2176-80. PubMed ID: 17870114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women.
    Serels S; Stein M
    Neurourol Urodyn; 1998; 17(1):31-6. PubMed ID: 9453690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.